$TMO (Thermo Fisher Scientific, Inc.)

$TMO {{ '2015-07-22T14:51:59+0000' | timeago}} • Webcast

$TMO 2Q15 Call: Revenues in Q2 were $4.27Bil in 2015 versus $4.32Bil in 2014. Organic revenue growth was 6%. Our adjusted operating income increased 3% to $951MM. We had good expansion in our adjusted operating margin, which increased 90BP to 22.3% & we delivered adjusted EPS of $1.84, which is 7% increase over Q2 of last year.

$TMO {{ '2017-07-26T14:06:23+0000' | timeago}} • Webcast

$TMO said the upward revision of 2017 financial outlook mainly reflected the less adverse foreign exchange environment. The company continues to expect 4% organic revenue growth for the year. Excluding the effect of foreign exchange headwinds, adjusted EPS is seen growing 12-14%. Adjusted operating margin is forecast to grow 50-60 basis points YoY.

$TMO {{ '2017-07-26T13:46:17+0000' | timeago}} • Webcast

Scientific equipment maker $TMO said pharma and biotec continued to be its strongest end markets in 2Q17, with mid-single digits growth. The company's growth strategy remains centered on launching innovative products and leveraging the scale in Asia Pacific and emerging markets. In 2Q17, Thermo Fisher completed $250MM of share buybacks.

$TMO {{ '2017-07-26T12:48:19+0000' | timeago}} • Infographic

$TMO Thermo Fisher Scientific, Inc. Earnings AlphaGraphic: Q2 2017 highlights

$TMO {{ '2017-07-26T10:56:26+0000' | timeago}} • Announcement

Among $TMO’s business segments, Life Sciences Solutions posted a 3% YoY growth in 2Q17 revenues. Analytical Instruments segment revenues surged 47%, reflecting the acquisition of FEI Company last year. Revenues of the Specialty Diagnostics segment and Laboratory Products & Services segment advanced 1% and 4%, respectively, compared to 2Q16.

$TMO {{ '2017-07-26T10:42:34+0000' | timeago}} • Announcement

$TMO revised up its fiscal 2017 revenue guidance to the range of $19.71-$19.89Bil from the previous outlook of $19.51-$19.71Bil, indicating an 8-9% annual growth. The guidance of adjusted EPS has been raised to $9.15-$9.28 per share from the earlier forecast of $9.12-$9.28 per share, which will result in an 11-12% YoY increase.

$TMO {{ '2017-07-26T10:33:50+0000' | timeago}} • Announcement

Medical instruments maker $TMO reported strong results for 2Q17, continuing the recent trend. Earnings of the company, which is currently on an acquisition spree, jumped 20% YoY to $1.56 per share. Adjusted earnings, excluding special items, grew 13% to $2.3 per share. The bottom line growth was driven by a 10% increase in revenues to $4.99Bil.

$TMO {{ '2017-07-19T12:44:47+0000' | timeago}} • Announcement

$TMO priced an offering of EUR2.6Bil of senior notes. The issuance of the notes is expected to close on or about July 24, 2017. $TMO plans to use all of net proceeds to fund a portion of consideration payable for its acquisition of Patheon, including the repayment of debt of Patheon to be assumed by $TMO, which is estimated to be about $7.2Bil.

$TMO {{ '2017-07-12T21:02:58+0000' | timeago}} • Announcement

$TMO declared a quarterly cash dividend of $0.15 per share, payable on October 16, 2017, to shareholders of record as of September 15, 2017.

$TMO {{ '2017-05-18T13:12:12+0000' | timeago}} • Announcement

$TMO declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on July 17, 2017, to shareholders of record as of June 15, 2017.

$TMO {{ '2017-04-26T14:19:48+0000' | timeago}} • Webcast

For 2017, $TMO expects modest organic growth for its microarray business. The company said it has launched a number of products and commercial initiatives for that business and that will help build some momentum moving through the course of 2017.

$TMO {{ '2017-04-26T14:13:04+0000' | timeago}} • Webcast

$TMO said roughly half of the margin expansion within Analytical Instruments segment in 1Q17 came from FEI acquisition. There is a good volume pull through in that segment and expects to drive additional revenue using the PPI (practical process improvement) business system, added the company.

$TMO {{ '2017-04-26T11:16:21+0000' | timeago}} • Announcement

In 1Q17, $TMO's revenue from Life Sciences Solutions segment grew 12% to $1.36Bil, while that from Analytical Instruments segment grew 39% to $1.05Bil. In other segments, Specialty Diagnostics revenue grew 1% to $866MM, and Laboratory Products and Services revenue grew 3% to $1.70Bil.

$TMO {{ '2017-04-26T11:11:01+0000' | timeago}} • Announcement

$TMO raised its revenue guidance for FY17 to a new range of $19.51-19.71Bil vs its original guidance of $19.38-19.62Bil announced in January 2017. Adjusted EPS guidance was raised to a range of $9.12-9.28 vs the $9.06-9.24 previously communicated.

$TMO {{ '2017-04-26T11:06:50+0000' | timeago}} • Announcement

Biotechnology product development company $TMO posted 11% growth in revenue to $4.77Bil in 1Q17. Organic revenue growth was 4%. Net income was $551.4MM, or $1.40 per share, better than $402MM, or $1.01 per share in 1Q16. Excluding one-off costs, net income rose to $2.08 per share.

$TMO {{ '2017-04-20T13:38:59+0000' | timeago}} • Announcement

$TMO signed an agreement with the Institute of Medical Genetics and Pathology at University Hospital Basel, Switzerland. This agreement will establish the leading institution as the first partner in the Next Generation Sequencing Companion Dx Center of Excellence Program.

$TMO {{ '2017-03-08T12:59:38+0000' | timeago}} • Announcement

$TMO stated that it plans to use approx. $508MM of the net proceeds from the offering of senior notes due 2027 to redeem the outstanding $500MM aggregate principal amount of its 1.850% senior notes that mature on January 15, 2018. $TMO intends to use any remaining net proceeds for general corporate purposes.

$TMO {{ '2017-03-08T12:58:26+0000' | timeago}} • Announcement

$TMO has priced an offering of EUR500MM aggregate principal amount of 1.450% senior notes due 2027 at an issue price of 98.824% of the principal amount. The issuance is expected to close on or about March 16, 2017. The notes will pay interest on an annual basis.

$TMO {{ '2017-03-06T15:34:02+0000' | timeago}} • Announcement

$TMO acquired Core Informatics, which provides a cloud-based platform supporting scientific data management. Core's offerings will significantly enhance $TMO's existing informatics solutions and complement its cloud platform, which supports the company's genetic analysis, qPCR and proteomics systems.

$TMO {{ '2017-03-01T15:41:49+0000' | timeago}} • Announcement

$TMO announced the election of Dion Weisler to its BoD, effective March 01, 2017. With this appointment the total number of $TMO board members has reached 12.

$TMO {{ '2017-02-28T21:34:50+0000' | timeago}} • Announcement

$TMO's BoD declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on April 17, 2017 to shareholders of record on March 15, 2017.

Recent Transcripts

LRCX (Lam Research Corporation)
Wednesday, July 26 2017 - 9:00pm
APH (Amphenol Corporation)
Wednesday, July 26 2017 - 5:00pm
NOC (Northrop Grumman Corporation)
Wednesday, July 26 2017 - 4:00pm
IEX (IDEX Corporation)
Wednesday, July 26 2017 - 2:30pm
BA (The Boeing Company)
Wednesday, July 26 2017 - 2:30pm
FLIR (FLIR Systems, Inc.)
Wednesday, July 26 2017 - 1:00pm
TMO (Thermo Fisher Scientific, Inc.)
Wednesday, July 26 2017 - 12:30pm
LPL (LG Display Co., Ltd.)
Wednesday, July 26 2017 - 1:00am
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
SNA (Snap-on Incorporated)
Thursday, July 20 2017 - 2:00pm
DHR (Danaher Corp.)
Thursday, July 20 2017 - 12:00pm
FCEL (FuelCell Energy Inc.)
Thursday, June 8 2017 - 2:00pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 9:00pm
GGB (Gerdau S.A.)
Thursday, May 4 2017 - 5:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 12:00pm
TSLA (Tesla, Inc.)
Wednesday, May 3 2017 - 9:30pm
CGNX (Cognex Corporation)
Monday, May 1 2017 - 9:00pm
ROP (Roper Technologies, Inc.)
Friday, April 28 2017 - 12:30pm
SNE (Sony Corporation)
Friday, April 28 2017 - 8:15am

AlphaGraphics you may like